GLG1 Inhibitors
Chemical inhibitors of GLG1 function by disrupting various enzymatic activities that are essential for the proper glycosylation and processing of glycoproteins, where GLG1 is known to play a critical role. Swainsonine, a potent inhibitor of mannosidase II, hampers the trimming of mannose residues during glycoprotein modification, a process essential for the maturation of glycoproteins that GLG1 helps facilitate. Castanospermine and its derivative, celgosivir, function by inhibiting glucosidase I and II, enzymes that catalyze the initial steps in glycoprotein processing. By impeding these steps, the chemicals directly affect the function of GLG1 in ensuring the correct folding and processing of glycoproteins.
In the same vein, Deoxynojirimycin and Deoxymannojirimycin, as α-glucosidase and mannosidase I inhibitors respectively, alter the glycosylation state of proteins, thereby influencing the maturation process that GLG1 is involved in. Kifunensine, also a mannosidase I inhibitor, has similar effects by obstructing the mannose trimming steps crucial for proper glycoprotein processing. Bromoconduritol and salbostatin, both glucosidase inhibitors, disrupt the glycan processing in the endoplasmic reticulum and Golgi apparatus, which would likely impair the role of GLG1 in glycoprotein maturation. Nojirimycin, by inhibiting several glycosidases, affects glycoprotein processing, crucial to GLG1's role in the cell. Lastly, Miglustat, although primarily a glucosylceramide synthase inhibitor, also exhibits activity against glycosidases, which can lead to altered glycoprotein processing, impacting GLG1's function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an indolizidine alkaloid known to inhibit mannosidase II, an enzyme involved in glycoprotein biosynthesis. GLG1 is implicated in glycoprotein processing; thus, swainsonine's inhibition of mannosidase II disrupts the glycosylation process crucial for GLG1's function in the Golgi apparatus. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is an indolizidine alkaloid that inhibits glucosidase I and II, enzymes responsible for the initial steps of glycoprotein processing in the endoplasmic reticulum and Golgi apparatus. By inhibiting these enzymes, the proper folding and processing of glycoproteins, a function associated with GLG1, are impeded. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin is an iminosugar that inhibits α-glucosidases, which are involved in the N-linked glycosylation of proteins. By inhibiting these enzymes, it can alter the glycosylation state of proteins, thereby potentially inhibiting the processing functions of GLG1 in glycoprotein maturation. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin is an iminosugar similar to deoxynojirimycin, but it primarily targets mannosidase I. As mannosidase I plays a role in glycoprotein processing, the inhibition of this enzyme would likely disrupt the normal function of GLG1 in the mannose trimming step of glycoprotein maturation. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that affects the glycosylation of proteins within the endoplasmic reticulum. Inhibition of this enzyme would impede the trimming of mannose residues, a necessary step for glycoprotein maturation, thus impacting GLG1's associated glycoprotein processing activities. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir is a prodrug of castanospermine and acts as a glucosidase I inhibitor. By targeting this enzyme, celgosivir can disrupt the initial glycosylation modification of nascent glycoproteins, impacting GLG1's associated functions. | ||||||